Home / Pharmaceuticals / Impetigo Treatment Market By Drug Class (Cephalosporins, Fusidane, Lincosamide, Penicillin, Penicillin-Like Antibiotics, Pleuromutilin, Pseudomonic Acid A, Quinolone, Sulfonamides And Folic Acid Inhibitors, Tetracyclines) - Growth, Future Prospects & Competitive Analysis, 2018-2026

Impetigo Treatment Market By Drug Class (Cephalosporins, Fusidane, Lincosamide, Penicillin, Penicillin-Like Antibiotics, Pleuromutilin, Pseudomonic Acid A, Quinolone, Sulfonamides And Folic Acid Inhibitors, Tetracyclines) - Growth, Future Prospects & Competitive Analysis, 2018-2026

Published: May 2018 | Report Code: 59146-05-18

Industry Outlook

The global impetigo treatment market expected to reach US$ 856.2 Mn by 2026 from US$ 448.6 Mn in 2017, growing at a CAGR of 7.3% during the forecast period from 2018 to 2026. Impetigo is a skin bacterial infection caused primarily by Staphylococcus aureus or Streptococcus pyogenes. These gram-positive bacteria infect the epidermal skin layer and cause highly contagious impetigo infection. The children are soft-targets for such pathogens and the infections with its huge prevalence in the areas with hot and humid climate. Depending on the causative agents, impetigo classification comprises non-bullous and bullous impetigo. Non-bullous impetigo is prevalent in 70% of the impetigo cases, accounts for around 10% of the all-cutaneous problems in pediatric clinics. It is primarily caused by Staphylococcus aureus or Streptococcus pyogenes or combination of both obverse to bullous form caused exclusively by S. aureus. The impetigo treatment majorly involves the infected wound care and prescription of topical or oral antibiotics.

The global impetigo treatment market is segmented based on the drug class for treatment into cephalosporins, fusidane, lincosamide, penicillin, penicillin-like antibiotics, pleuromutilin, pseudomonic acid A, quinolone, sulfonamides and folic acid inhibitors, and tetracyclines. The drug classes are available in topical agent or oral form, topical being predominantly prescribed due to effective results. The impetigo treatment market expected to surge during the forecast period owing to the growing incidence of the infection and development of novel therapeutics. However, the evolution of Methicillin-resistant S. aureus (MRSA) and macrolide-resistant Streptococcus is a major challenge to the treatment and forces manufacturer for the development of more efficient antibiotics, thereby contributing to the growth of the market. Thus, the impetigo treatment market provides enormous opportunities to the manufacturers as the impetigo incidence is rising and the healthcare infrastructure is growing in developing countries. 

Market Synopsis

Table: Global Impetigo Treatment Market Portraiture

Impetigo Treatment Market

Get a sample copy for more information

"Penicillin & Penicillin-Like Antibiotics Expected to Drive the Market during the Forecast Period"

In 2017, penicillin and penicillin-like antibiotics together accounted for over 34% of the global impetigo treatment market. The two segments collectively expected to drive the global market. Antibiotics treatment is preferred to reduce the healing duration as most of the impetigo infections are resolved naturally. According to the Infectious Diseases Society of America, the impetigo should be treated with the topical antibiotics for 5 to 7 days such as pseudomonic acid A. Fusidic acid, another topical agent, is not available in the United States, however, physicians in Europe recommend fusidic acid or pseudomonic acid A as the first line of topical antibiotics. The market will surge during the forecast period owing to the development of novel drugs.

Impetigo Treatment Market

Get a sample copy for more information

"North America will Continue to Retain its Dominance during the Forecast Period"

In 2017, North America led the global impetigo treatment market with around 34% of the market share, in terms of value. The United States dominated the North America market due to presence of healthcare infrastructure and high awareness regarding impetigo. The regional market will proliferate due to early drug approval in the United States that aids in early market capturing compared to rest of major economic regions. Europe follows North America, in terms of market value, due to high awareness of impetigo. Asia Pacific is the most lucrative market for impetigo due to the growing healthcare infrastructure and rising awareness of skin infections. Furthermore, the prime incidence of impetigo infections in hot and humid areas account for more infections in Asia Pacific, thereby accounting for the growth of the market.

Impetigo Treatment Market

Get a sample copy for more information

"Focus on the Research and Development for Novel Drug Molecules expected to Fuel the Market"

With the growing usage of the antibiotics, the microorganisms are adapting to current antibiotics through genome modifications, which hinders the treatment pattern. Many studies had reported methicillin-resistant S aureus (MRSA) and macrolide-resistant Streptococcus earlier and current studies have reported fusidic acid resistant bacteria. The evolvement of these microbes burdens the manufacturers to develop effective treatment options, which expected to fuel the market growth. For instance, NovaBay Pharmaceuticals, Inc. is developing NVC-422 (topical agent) that is currently in phase II/III for impetigo treatment. The same molecule is in phase II for catheter infections. The product has performed well in early phases and expected to launch during the forecast period. Thus, the focus of manufacturer on the research and development for novel drug molecules expected to fuel the market. Key players in impetigo treatment market include GlaxoSmithKline plc, Karalex Pharma, LLC, Leo Pharma A/S, Lupin Limited, NovaBay Pharmaceuticals, Inc., Pfizer, Inc., Ranbaxy Laboratories Limited, Roche Holding AG, SANDOZ GmbH, Taro Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd.

Impetigo Treatment Market

Historical & Forecast Period

The research is performed by considering 2017 as the base for the study and 2018 to 2026 as the forecast period.

Report Scope by Segments

For the better understanding, the market is segmented based upon the drug class and geography. The purpose for publishing this report is to aid the market investors in decision making and taking strategic initiatives.

ATTRIBUTE DETAILS
Research Period  2016-2026
Base Year 2017
Forecast Period  2018-2026
Historical Year  2016
Unit  USD Million
Segmentation

 Drug Class Segment (2016–2026; US$ Mn)
 • Cephalosporins
 • Fusidane
 • Lincosamide Antibiotic
 • Penicillin
 • Penicillin-Like Antibiotics
 • Pleuromutilin
 • Pseudomonic Acid A
 • Quinolone
 • Sulfonamides And Folic Acid Inhibitors
 • Tetracyclines
 • Pipeline Analysis
   o Phase III
      NVC-422
   o Phase I & II

 Geography Segment (2016–2026; US$ Mn)
 • North America (U.S., Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (Japan, China, Rest of APAC)
 • Latin America (Brazil, Mexico, Rest of LATAM)
 • Middle East and Africa (GCC, Rest of MEA)

Along with the market quantification, the key qualitative market factors such as drivers, restraints and opportunities are also included in the report. Furthermore, the players are mapped based their business strength and product offering. Key players profiled in the report include GlaxoSmithKline plc, Karalex Pharma, LLC, Leo Pharma A/S, Lupin Limited, NovaBay Pharmaceuticals, Inc., Pfizer, Inc., Ranbaxy Laboratories Limited, Roche Holding AG, SANDOZ GmbH, Taro Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Key questions answered in this report

  • Which are the prominent drug classes or drugs prescribed as the first line of treatment in impetigo?
  • What will be the effect of approval of pipeline products in Japan?
  • What are the market trends in the impetigo treatment market?
  • Which prominent geographies are appropriate for new product launch?
  • What is the size of Europe impetigo treatment market, and how the other regional markets stand in the global competition?
  • Which developing countries have huge potential for impetigo treatment market?

Chapter 1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Market Segmentation
1.3. Research Scope
1.4. Research Methodology
1.4.1. Phase I - Secondary Research
1.4.2. Phase II - Primary Research
1.4.3. Phase III - Expert Panel Review
1.4.4. Assumptions

Chapter 2. Executive Summary
2.1. Global IT Market Portraiture
2.2. Global IT Market, by Drug Class, 2017 (US$ Mn)
2.3. Global IT Market, by Geography, 2017 (US$ Mn)

Chapter 3. Global Impetigo Treatment (IT) Market: Dynamics and Future Outlook
3.1. Overview
3.2. Market Dynamics
3.2.1. Drivers
3.2.1.1. Increasing Number of Impetigo Cases Leading to Growing Medical Attention
3.2.1.2. Driver 2
3.2.2. Challenges
3.2.2.1. Challenge 1
3.2.2.2. Challenge 2
3.2.3. Opportunities
3.2.3.1. Opportunity 1
3.3. Attractive Investment Proposition, by Geography, 2017
3.4. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Impetigo Treatment (IT) Market, by Drug Class, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Cephalosporins
4.3. Fusidane
4.4. Lincosamide
4.5. Penicillin
4.6. Penicillin-like Antibiotics
4.7. Pleuromutilin
4.8. Pseudomonic Acid A
4.9. Quinolone
4.10. Sulfonamides And Folic Acid Inhibitors
4.11. Tetracyclines
4.12. Pipeline Analysis
4.12.1. Phase III (Market estimations by 2026)
4.12.1.1. NVC-422 (NovaBay Pharmaceuticals)
4.12.2. Phase II & I (Tabular Information)

Chapter 5. Global Impetigo Treatment (IT) Market, by Geography, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. North America IT Market, 2016 - 2026 (US$ Mn)
5.2.1. North America IT Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.2.2. North America IT Market, by Country, 2016 - 2026 (US$ Mn)
5.2.2.1. United States
5.2.2.2. Canada
5.3. Europe IT Market, 2016 - 2026 (US$ Mn)
5.3.1. Europe IT Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.3.2. Europe IT Market, by Country/Region, 2016 - 2026 (US$ Mn)
5.3.2.1. United Kingdom
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific IT Market, 2016 - 2026 (US$ Mn)
5.4.1. Asia Pacific IT Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.4.2. Asia Pacific IT Market, by Country/Region, 2016 - 2026 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America IT Market, 2016 - 2026 (US$ Mn)
5.5.1. Latin America IT Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.5.2. Latin America IT Market, by Country/Region, 2016 - 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa IT Market, 2016 - 2026 (US$ Mn)
5.6.1. Middle East & Africa IT Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.6.2. Middle East & Africa IT Market, by Region, 2016 - 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. GlaxoSmithKline plc
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Karalex Pharma, LLC
6.3. Leo Pharma A/S
6.4. Lupin Limited
6.5. NovaBay Pharmaceuticals, Inc.
6.6. Pfizer, Inc.
6.7. Ranbaxy Laboratories Limited
6.8. Roche Holding AG
6.9. SANDOZ GmbH
6.10. Taro Pharmaceutical Industries Ltd.
6.11. Teva Pharmaceutical Industries Ltd.

* IT - Impetigo Treatment

FIG. 1 Market Segmentation: Global Impetigo Treatment (IT) Market
FIG. 2 Research Methodology: Global IT Market
FIG. 3 Global IT Market, by Drug Class, 2017 (US$ Mn)
FIG. 4 Global IT Market, by Geography, 2017 (US$ Mn)
FIG. 5 Attractive Investment Proposition: Global IT Market, by Geography, 2017
FIG. 6 Competitive Landscape, by Key Players, 2017
FIG. 7 Global Cephalosporins Market for IT, 2016 - 2026 (US$ Mn)
FIG. 8 Global Fusidane Market for IT, 2016 - 2026 (US$ Mn)
FIG. 9 Global Lincosamide Market for IT, 2016 - 2026 (US$ Mn)
FIG. 10 Global Penicillin Market for IT, 2016 - 2026 (US$ Mn)
FIG. 11 Global Penicillin-like Antibiotics Market for IT, 2016 - 2026 (US$ Mn)
FIG. 12 Global Pleuromutilin Market for IT, 2016 - 2026 (US$ Mn)
FIG. 13 Global Pseudomonic Acid A Market for IT, 2016 - 2026 (US$ Mn)
FIG. 14 Global Quinolone Market for IT, 2016 - 2026 (US$ Mn)
FIG. 15 Global Sulfonamides And Folic Acid Inhibitors Market for IT, 2016 - 2026 (US$ Mn)
FIG. 16 Global Tetracyclines Market for IT, 2016 - 2026 (US$ Mn)
FIG. 17 Global NVC-422 Market for IT, 2016 - 2026 (US$ Mn)
FIG. 18 U.S. IT Market, 2016 - 2026 (US$ Mn)
FIG. 19 Canada IT Market, 2016 - 2026 (US$ Mn)
FIG. 20 U.K. IT Market, 2016 - 2026 (US$ Mn)
FIG. 21 Germany IT Market, 2016 - 2026 (US$ Mn)
FIG. 22 Rest of Europe IT Market, 2016 - 2026 (US$ Mn)
FIG. 23 China IT Market, 2016 - 2026 (US$ Mn)
FIG. 24 Japan IT Market, 2016 - 2026 (US$ Mn)
FIG. 25 Rest of Asia Pacific IT Market, 2016 - 2026 (US$ Mn)
FIG. 26 Brazil IT Market, 2016 - 2026 (US$ Mn)
FIG. 27 Mexico IT Market, 2016 - 2026 (US$ Mn)
FIG. 28 Rest of Latin America IT Market, 2016 - 2026 (US$ Mn)
FIG. 29 GCC IT Market, 2016 - 2026 (US$ Mn)
FIG. 30 Rest of Middle East and Africa IT Market, 2016 - 2026 (US$ Mn)

TABLE 1. Global Impetigo Treatment (IT) Market Portraiture
TABLE 2. Global IT Market, by Drug Class, 2016 - 2026 (US$ Mn)
TABLE 3. Global IT Market, by Geography, 2016 - 2026 (US$ Mn)
TABLE 4. North America IT Market, by Drug Class, 2016 - 2026 (US$ Mn)
TABLE 5. North America IT Market, by Country, 2016 - 2026 (US$ Mn)
TABLE 6. Europe IT Market, by Drug Class, 2016 - 2026 (US$ Mn)
TABLE 7. Europe IT Market, by Country/Region, 2016 - 2026 (US$ Mn)
TABLE 8. Asia Pacific IT Market, by Drug Class, 2016 - 2026 (US$ Mn)
TABLE 9. Asia Pacific IT Market, by Country/Region, 2016 - 2026 (US$ Mn)
TABLE 10. Latin America IT Market, by Drug Class, 2016 - 2026 (US$ Mn)
TABLE 11. Latin America IT Market, by Country/Region, 2016 - 2026 (US$ Mn)
TABLE 12. Middle East and Africa IT Market, by Drug Class, 2016 - 2026 (US$ Mn)
TABLE 13. Middle East and Africa IT Market, by Region, 2016 - 2026 (US$ Mn)
TABLE 14. GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 15. Karalex Pharma, LLC: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16. Leo Pharma A/S: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17. Lupin Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18. NovaBay Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19. Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20. Ranbaxy Laboratories Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21. Roche Holding AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22. SANDOZ GmbH: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23. Taro Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24. Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Our Clients